Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Amy D. Horton filed a Form 144 reporting an intended sale of 901 shares of Common stock. The filing lists the securities to be sold as 901 shares tied to 02/27/2026 described as Restricted Stock Vesting under compensation.
The filing also discloses prior market sales of Common stock during the past three months: 4,572 shares on 12/08/2025 for $203,081.38, 1,731 shares on 02/23/2026 for $65,063.96, 830 shares on 02/24/2026 for $29,625.11, and 641 shares on 03/02/2026 for $24,373.96.
Artivion, Inc. executive reports tax-related share sale. VP and Chief Accounting Officer Amy Horton disposed of 641 shares of common stock in an open-market transaction at about $38.02 per share. According to the footnote, the shares were sold automatically to cover tax withholding upon restricted stock unit vesting and were not a discretionary trade. After this transaction, she directly holds 132,514 shares.
Artivion, Inc. senior vice president Stanton Marshall S. reported an automatic sale of 1,513 shares of common stock at an average price of $38.0249 per share. According to the filing, the shares were sold upon vesting of restricted stock units solely to cover tax withholding obligations and were not a discretionary trade. After this transaction, he directly holds 40,408 shares of Artivion common stock.
Artivion, Inc. President and CEO James P. Mackin reported an open-market sale of 14,911 shares of common stock at an average price of $38.0249 per share. According to the footnote, the shares were sold solely to cover tax withholding obligations upon the vesting of restricted stock units and did not represent a discretionary transaction. After this sale, Mackin beneficially owned 848,214 shares of Artivion common stock directly.
Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported an automatic sale of company stock related to tax withholding. On this Form 4, she disposed of 2,183 shares of common stock at a weighted average price of $38.0249 per share in an open-market transaction. A footnote explains that the shares were sold upon the vesting of restricted stock units solely to cover tax withholding obligations through a “sell to cover” arrangement and did not represent a discretionary trade. After this transaction, Holloway directly owned 170,105 shares of Artivion common stock.
Artivion, Inc. executive Lance A. Berry reported a tax-related share sale. On this Form 4, the EVP, COO, CFO & Treasurer sold 5,178 shares of common stock at an average price of $38.0249 per share in connection with the vesting of restricted stock units.
The filing explains that the shares were sold solely to satisfy tax withholding obligations through a “sell to cover” arrangement and is described as a non-discretionary transaction rather than an elective open-market sale. After this transaction, Berry directly holds 176,269 shares of Artivion common stock.
ARTIVION, INC. Chief Commercial Officer John E. Davis reported an open-market sale of 2,784 shares of common stock. The shares were sold at an average price of $38.0249 per share in connection with the vesting of restricted stock units to cover tax withholding obligations.
After this sell-to-cover, Davis directly holds 206,522 shares of Artivion common stock. The filing states that this transaction was not discretionary and was executed solely to satisfy required tax withholding on equity compensation.
AORT reported a Form 144 notice regarding the proposed sale of 2,183 shares of Common stock tied to restricted stock vesting on 02/27/2026. The filing also discloses prior sales by Jean F. Holloway of 3,079 shares on 02/23/2026 and 1,668 shares on 02/24/2026.
The issuer filed a Form 144 related to the proposed sale of 14,911 common shares tied to restricted stock vesting dated 02/27/2026. The excerpt also lists recent sales by James Mackin: 30,921 shares on 12/02/2025 for $1,408,736.02, 30,921 shares on 12/03/2025 for $1,405,693.40, 20,962 shares on 02/23/2026 for $787,909.17, and 13,936 shares on 02/24/2026 for $497,416.25.
AORT submitted a Form 144 notice disclosing a proposed sale of 2,784 common shares with an aggregate value of $105,861.32. The filing lists the transaction type as Restricted Stock Vesting and shows the sale notice dated 03/02/2026.
The form also records recent dispositions by John E. Davis of 3,773 shares on 02/23/2026 and 2,075 shares on 02/24/2026, with aggregate amounts shown for each sale.